Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | GPR6 | P46095 | 4/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27138787 | 0.85 | USP30 (0.47) | USP30GPR6SLC6A9 | |
| SCHEMBL223791 | 0.84 | GPR119 (0.64) | GPR119GPR6ALK | |
| SCHEMBL18357619 | 0.83 | GPR119 (0.47) | GPR119USP30EGLN2TNFIRAK4 | |
| SCHEMBL21886989 | 0.82 | GPR119 (0.56) | GPR119USP30GPR6ALK | |
| SCHEMBL30013019 | 0.82 | USP30 (0.42) | GPR119USP30GPR6SLC6A9 | |
| SCHEMBL25295322 | 0.78 | ABHD6 (0.46) | GPR119 | |
| SCHEMBL27152201 | 0.76 | ABHD6 (0.51) | GPR119 | |
| SCHEMBL18357785 | 0.76 | EGLN2 (0.51) | GPR119EGLN2IRAK4ALK | |
| SCHEMBL30490303 | 0.76 | GPR119 (0.54) | GPR119 | |
| SCHEMBL28417505 | 0.75 | GPR119 (0.49) | GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4326714-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022223750-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | GPR119 1925/4885USP30 3172/4885EGLN2 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.